Page 12 - மருந்து பாதுகாப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Intellipharmaceutics Announces Second Quarter 2021 Results ACCESSWIRE 16 Jul 2021, 06:55 GMT+10 TORONTO, ON / ACCESSWIRE / July 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ( Intellipharmaceutics or the Company ), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2021. All dollar amounts referenced herein are in United States dollars unless otherwise noted. Effective May 5, 2021 our exclusive license agreements with Tris Pharma, Inc. for generic Seroquel XR®, generic Pristiq® and generic Effexor XR® were mutually terminated. Products were never supplied nor distributed under the licenses. Termination of the exclusive agreements may provide opportunity for the Company to explore options of supplying the products to multiple sources on non-exclusiv

United statesPurdue pharmaIsa odidiCompany oxycodoneCompany contactParty transactionCompany the commonUnited states district courtRisk management advisory committeeTris pharma incDrug products advisory committeeToronto stock exchangeIntellipharmaceutics international incCompany aximrisHealth canadaIntellipharmaceutics international